Evidence map›Paper›PMID 38950871›Full record

ReviewThe Journal of steroid biochemistry and molecular biology2024

Glucocorticoid receptors orchestrate a convergence of host and cellular stress signals in triple negative breast cancer.

Sai Harshita Posani, Noelle E Gillis, Carol A Lange

Abstract readReview
In one paragraph

Review in The Journal of steroid biochemistry and molecular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sai Harshita PosaniMolecular Pharmacology and Therapeutics Program, University of Minnesota, Minneapolis 55455, United States; Department of Pharmacology, University of Minnesota, Minneapolis 55455, United States.
Noelle E GillisMasonic Cancer Center, University of Minnesota, Minneapolis 55455, United States.
Carol A LangeMasonic Cancer Center, University of Minnesota, Minneapolis 55455, United States; Department of Medicine (Division of Hematology, Oncology, and Transplantation), University of Minnesota, Minneapolis 55455, United States; Department of Pharmacology, University of Minnesota, Minneapolis 55455, United States. Electronic address: lange047@umn.edu.

Funding

Progesterone Receptor (PR) Signaling Cross Talk Drives ER+ Breast CancerR01CA229697 · NCI · UNIVERSITY OF MINNESOTA · PI Carol A Lange, Douglas Yee · 2020 to 2026
$3.6M
Inducible PTK6 expression drives oncogenic signaling in breast cancerR01CA192178 · NCI · UNIVERSITY OF MINNESOTA · PI LANGE, CAROL A · 2015 to 2019
$2.2M
Brk signal transduction in breast cancerR01CA107547 · NCI · UNIVERSITY OF MINNESOTA · PI LANGE, CAROL A · 2007 to 2011
$1.3M
Nuclear Receptor Regulation of Epigenetics in Endocrine-Related CancersK00CA245796 · NCI · UNIVERSITY OF MINNESOTA · PI GILLIS, NOELLE ELIZABETH · 2021 to 2024
$366k
Nuclear Receptor Regulation of Epigenetics in Endocrine-Related CancersF99CA245796 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI GILLIS, NOELLE ELIZABETH · 2019 to 2020
$67k
NCI NIH HHS F99 CA245796NCI NIH HHS K00 CA245796NCI NIH HHS R01 CA107547NCI NIH HHS R01 CA192178NCI NIH HHS R01 CA229697
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks expression of the nuclear steroid receptors that bind estrogens (ER) and progestogens (PRs) and does not exhibit HER2 (Human epidermal growth factor 2) receptor overexpression. Even in the face of initially effective chemotherapies, TNBC patients often relapse. One primary cause for therapy-resistant tumor progression is the activation of cellular stress signaling pathways. The glucocorticoid receptor (GR), a corticosteroid-activated transcription factor most closely related to PR, is a mediator of both endocrine/host stress and local tumor microenvironment (TME)-derived and cellular stress responses. Interestingly, GR expression is associated with a good prognosis in ER+ breast cancer but predicts poor prognosis in TNBC. Classically, GR's transcriptional activity is regulated by circulating glucocorticoids. Additionally, GR is regulated by ligand-independent signaling events. Notably, the stress-activated protein kinase, p38 MAP kinase, phosphorylates GR at serine 134 (Ser134) in response to TME-derived growth factors and cytokines, including HGF and TGFβ1. Phospho-Ser134-GR (p-Ser134-GR) associates with cytoplasmic and nuclear signaling molecules, including 14-3-3ζ, aryl hydrocarbon receptors (AhR), and hypoxia-inducible factors (HIFs). Phospho-GR/HIF-containing transcriptional complexes upregulate gene sets whose protein products include the components of inducible oncogenic signaling pathways (PTK6) that further promote cancer cell survival, chemoresistance, altered metabolism, and migratory/invasive behavior in TNBC. Recent studies have implicated liganded p-Ser134-GR (p-GR) in dexamethasone-mediated upregulation of genes related to TNBC cell motility and dysregulated metabolism. Herein, we review the tumor-promoting roles of GR and discuss how both ligand-dependent and ligand-independent/stress signaling-driven inputs to p-GR converge to orchestrate metastatic TNBC progression.

Indexed as

Receptors, GlucocorticoidSignal TransductionTriple Negative Breast NeoplasmsAnimalsFemaleGene Expression Regulation, NeoplasticHumansStress, PhysiologicalTumor MicroenvironmentReceptors, GlucocorticoidGlucocorticoidsSteroid receptorsStress signalingTriple negative breast cancerTumor microenvironment

Identifiers

PMID38950871
PMCPMC11344665

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.